Search ( Ctrl + / )

VRTX

Vertex Pharmaceuticals

VRTXNASDAQ

$500.19

-0.96

0.19%

Last Updated: May 5, 20:00

VRTX Financials

Search ( Ctrl + / )

VRTX

Vertex Pharmaceuticals

VRTXNASDAQ

$500.19

-0.96

0.19%

Last Updated: May 5, 20:00

VRTX Financials

	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Statement Date	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Revenue	2.77B	2.63B	2.69B	2.52B	2.48B	2.49B	2.37B	2.30B
Cost of Revenue	392.60M	371.90M	342.60M	368.00M	318.70M	308.60M	266.90M	283.30M
Gross Profit	2.38B	2.26B	2.34B	2.15B	2.16B	2.18B	2.11B	2.02B
Gross Profit Ratio	0.86	0.86	0.87	0.85	0.87	0.88	0.89	0.88
Research and Development Expenses	875.90M	5.42B	865.90M	821.80M	810.00M	785.70M	742.60M	694.10M
General and Administrative Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling and Marketing Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Expenses	15.30M	-23.10M	-31.20M	-9.80M	-15.90M	1.60M	1.30M	24.40M
Operating Expenses	1.26B	5.79B	1.21B	1.19B	1.07B	1.05B	983.70M	985.90M
Cost and Expenses	1.66B	6.16B	1.55B	1.56B	1.39B	1.36B	1.25B	1.27B
Interest Expense	7.50M	9.90M	10.40M	10.60M	10.90M	11.20M	11.40M	11.60M
Depreciation and Amortization	53.20M	54.00M	53.50M	59.00M	204.90M	256.20M	469.10M	38.40M
EBITDA	1.28B	-3.33B	1.34B	1.02B	1.24B	1.28B	1.25B	1.13B
EBITDA Ratio	0.46	-1.32	0.44	0.40	0.50	0.51	0.53	0.49
Operating Income	1.12B	-3.53B	1.14B	958.80M	1.04B	1.03B	779.00M	1.03B
Operating Income Ratio	0.40	-1.34	0.42	0.38	0.42	0.41	0.33	0.45
Total Other Income Expenses	107.80M	123.50M	139.60M	188.80M	-68.80M	-108.30M	112.50M	43.30M
Income Before Tax	1.22B	-3.39B	1.28B	1.15B	1.18B	1.16B	891.50M	1.08B
Income Before Tax Ratio	0.44	-1.29	0.48	0.46	0.47	0.47	0.38	0.47
Income Tax Expense	178.70M	202.40M	179.50M	178.80M	143.90M	245.80M	191.70M	257.90M
Net Income	1.05B	-3.59B	1.10B	968.80M	1.04B	915.70M	699.80M	818.90M
Net Income Ratio	0.38	-1.36	0.41	0.38	0.42	0.37	0.29	0.36
EPS	4.05	-13.92	4.26	3.76	4.01	3.55	2.72	3.19

	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Statement Date	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Revenue	2.77B	2.63B	2.69B	2.52B	2.48B	2.49B	2.37B	2.30B
Cost of Revenue	392.60M	371.90M	342.60M	368.00M	318.70M	308.60M	266.90M	283.30M
Gross Profit	2.38B	2.26B	2.34B	2.15B	2.16B	2.18B	2.11B	2.02B
Gross Profit Ratio	0.86	0.86	0.87	0.85	0.87	0.88	0.89	0.88
Research and Development Expenses	875.90M	5.42B	865.90M	821.80M	810.00M	785.70M	742.60M	694.10M
General and Administrative Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling and Marketing Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Expenses	15.30M	-23.10M	-31.20M	-9.80M	-15.90M	1.60M	1.30M	24.40M
Operating Expenses	1.26B	5.79B	1.21B	1.19B	1.07B	1.05B	983.70M	985.90M
Cost and Expenses	1.66B	6.16B	1.55B	1.56B	1.39B	1.36B	1.25B	1.27B
Interest Expense	7.50M	9.90M	10.40M	10.60M	10.90M	11.20M	11.40M	11.60M
Depreciation and Amortization	53.20M	54.00M	53.50M	59.00M	204.90M	256.20M	469.10M	38.40M
EBITDA	1.28B	-3.33B	1.34B	1.02B	1.24B	1.28B	1.25B	1.13B
EBITDA Ratio	0.46	-1.32	0.44	0.40	0.50	0.51	0.53	0.49
Operating Income	1.12B	-3.53B	1.14B	958.80M	1.04B	1.03B	779.00M	1.03B
Operating Income Ratio	0.40	-1.34	0.42	0.38	0.42	0.41	0.33	0.45
Total Other Income Expenses	107.80M	123.50M	139.60M	188.80M	-68.80M	-108.30M	112.50M	43.30M
Income Before Tax	1.22B	-3.39B	1.28B	1.15B	1.18B	1.16B	891.50M	1.08B
Income Before Tax Ratio	0.44	-1.29	0.48	0.46	0.47	0.47	0.38	0.47
Income Tax Expense	178.70M	202.40M	179.50M	178.80M	143.90M	245.80M	191.70M	257.90M
Net Income	1.05B	-3.59B	1.10B	968.80M	1.04B	915.70M	699.80M	818.90M
Net Income Ratio	0.38	-1.36	0.41	0.38	0.42	0.37	0.29	0.36
EPS	4.05	-13.92	4.26	3.76	4.01	3.55	2.72	3.19